MARKET

SLS

SLS

Sellas Life Sciences Group Inc
NASDAQ
12.78
+0.42
+3.40%
After Hours: 12.77 -0.01 -0.08% 18:20 08/14 EDT
OPEN
12.40
PREV CLOSE
12.36
HIGH
13.00
LOW
12.18
VOLUME
4.39M
TURNOVER
--
52 WEEK HIGH
15.88
52 WEEK LOW
1.390
MARKET CAP
2.58B
P/E (TTM)
-54.9441
1D
5D
1M
3M
1Y
5Y
1D
This One Data Readout Could Make Or Break Sellas Life Sciences Group
Seeking Alpha · 1d ago
Sellas Net Loss Widens In Q2; Phase 2 SLS009 Readout Due In Q4 2026; Stock Up
NASDAQ · 2d ago
SELLAS Life Sciences GAAP EPS of -$0.05 misses by $0.01
Seeking Alpha · 3d ago
Sellas Life Sciences reports wider loss as REGAL trial nears final analysis
Seeking Alpha · 3d ago
SELLAS Life Sciences Gr Q2 EPS $(0.05) Misses $(0.04) Estimate
Benzinga · 3d ago
Press Release: SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Dow Jones · 3d ago
Press Release: SELLAS Life Sciences Reports -2-
Dow Jones · 3d ago
Sellas Life Sciences options imply 8.0% move in share price post-earnings
TipRanks · 3d ago
More
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of therapeutics for a range of cancer indications. The Company's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.

Webull offers Sellas Life Sciences Group Inc stock information, including NASDAQ: SLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLS stock methods without spending real money on the virtual paper trading platform.